NASDAQ:PHVS Pharvaris (PHVS) Stock Price, News & Analysis $13.21 -1.07 (-7.49%) Closing price 04/7/2025 04:00 PM EasternExtended Trading$13.06 -0.15 (-1.10%) As of 04/7/2025 07:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Pharvaris Stock (NASDAQ:PHVS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Pharvaris alerts:Sign Up Key Stats Today's Range$12.68▼$14.0650-Day Range$13.21▼$18.2952-Week Range$12.68▼$25.50Volume25,436 shsAverage Volume71,610 shsMarket Capitalization$690.75 millionP/E RatioN/ADividend YieldN/APrice Target$40.50Consensus RatingBuy Company OverviewPharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial. The company operates in the Netherlands, Switzerland, and the United States. Pharvaris N.V. was incorporated in 2015 and is based in Leiden, the Netherlands.Read More… Remove Ads Pharvaris Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks23rd Percentile Overall ScorePHVS MarketRank™: Pharvaris scored higher than 23% of companies evaluated by MarketBeat, and ranked 828th out of 901 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingPharvaris has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoveragePharvaris has only been the subject of 1 research reports in the past 90 days.Read more about Pharvaris' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Pharvaris are expected to decrease in the coming year, from ($2.71) to ($3.06) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Pharvaris is -4.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Pharvaris is -4.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPharvaris has a P/B Ratio of 1.66. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Pharvaris' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted3.35% of the float of Pharvaris has been sold short.Short Interest Ratio / Days to CoverPharvaris has a short interest ratio ("days to cover") of 12.7, which indicates bearish sentiment.Change versus previous monthShort interest in Pharvaris has recently increased by 18.55%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPharvaris does not currently pay a dividend.Dividend GrowthPharvaris does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted3.35% of the float of Pharvaris has been sold short.Short Interest Ratio / Days to CoverPharvaris has a short interest ratio ("days to cover") of 12.7, which indicates bearish sentiment.Change versus previous monthShort interest in Pharvaris has recently increased by 18.55%, indicating that investor sentiment is decreasing significantly. News and Social Media1.8 / 5News Sentiment0.21 News SentimentPharvaris has a news sentiment score of 0.21. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.63 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 12 news articles for Pharvaris this week, compared to 2 articles on an average week. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Pharvaris insiders have not sold or bought any company stock.Percentage Held by Insiders11.84% of the stock of Pharvaris is held by insiders. A high percentage of insider ownership can be a sign of company health.Read more about Pharvaris' insider trading history. Receive PHVS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pharvaris and its competitors with MarketBeat's FREE daily newsletter. Email Address PHVS Stock News HeadlinesPharvaris Reports 2024 Financial Results and Business ProgressApril 8 at 12:21 AM | tipranks.comPharvaris Reports 2024 Financial Results and Advances HAE Treatment StudiesApril 7 at 7:30 AM | tipranks.comElon Musk Demands Fort Knox AuditWith gold prices recently soaring to record highs over $3,000 an ounce, and central banks rushing to accumulate more of the precious metal, the timing couldn't be more critical. If the gold reserves in Fort Knox are found to be less than officially reported, we could see gold prices skyrocket virtually overnight.April 8, 2025 | The Oxford Club (Ad)Pharvaris Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdateApril 7 at 7:08 AM | gurufocus.comPharvaris Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdateApril 7 at 6:58 AM | globenewswire.comPharvaris says EC grants orphan designation to deucrictibantApril 2, 2025 | markets.businessinsider.comPharvaris (PHVS) to Release Quarterly Earnings on WednesdayApril 2, 2025 | americanbankingnews.comPharvaris Announces Orphan Designation Granted to Deucrictibant by the European CommissionApril 1, 2025 | globenewswire.comSee More Headlines PHVS Stock Analysis - Frequently Asked Questions How have PHVS shares performed this year? Pharvaris' stock was trading at $19.17 on January 1st, 2025. Since then, PHVS stock has decreased by 31.1% and is now trading at $13.21. View the best growth stocks for 2025 here. How were Pharvaris' earnings last quarter? Pharvaris (NASDAQ:PHVS) posted its quarterly earnings data on Wednesday, April, 9th. The company reported ($0.68) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.74) by $0.06. When did Pharvaris IPO? Pharvaris (PHVS) raised $126 million in an initial public offering (IPO) on Friday, February 5th 2021. The company issued 7,000,000 shares at a price of $17.00-$19.00 per share. Morgan Stanley, BofA Securities and SVB Leerink acted as the underwriters for the IPO and Oppenheimer & Co. and Kempen & Co. were co-managers. How do I buy shares of Pharvaris? Shares of PHVS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Pharvaris own? Based on aggregate information from My MarketBeat watchlists, some other companies that Pharvaris investors own include NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), e.l.f. Beauty (ELF), Jabil (JBL), Disc Medicine (IRON) and Adobe (ADBE). Company Calendar Today4/08/2025Last Earnings4/09/2025Next Earnings (Estimated)4/09/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:PHVS CIK1830487 Webwww.pharvaris.com Phone31-71-203-6410FaxN/AEmployees30Year FoundedN/APrice Target and Rating Average Stock Price Target$40.50 High Stock Price Target$55.00 Low Stock Price Target$31.00 Potential Upside/Downside+206.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($2.80) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-109,180,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-38.52% Return on Assets-36.69% Debt Debt-to-Equity RatioN/A Current Ratio19.08 Quick Ratio19.08 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$7.95 per share Price / Book1.66Miscellaneous Outstanding Shares52,290,000Free Float46,099,000Market Cap$690.75 million OptionableNot Optionable Beta-2.84 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free Report This page (NASDAQ:PHVS) was last updated on 4/8/2025 by MarketBeat.com Staff From Our PartnersFeds Just Admitted It—They Can Take Your CashThe Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money i...Priority Gold | SponsoredAmazon ShockerJeff Bezos quietly backing world-changing tech (not AI) The Amazon founder is quietly advancing a radical t...Stansberry Research | SponsoredThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredThese obscure companies are Trump’s favorites?Ten investments secretly owned by Trump’s biggest backers. Ten investments intrinsically tied to the polici...Porter & Company | SponsoredYour Retirement Is Caught in the CrossfireWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredGold Hits $3,000… Here’s How You Can Get More for Under $20With gold surging to record highs, currently trading above $3,000 an ounce, and central banks aggressively sto...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pharvaris Please log in to your account or sign up in order to add this asset to your watchlist. Share Pharvaris With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.